PTH and secondary hyperparathyroidism: Secondary hyperparathyroidism (SHPT) is often observed in patients with end-stage renal disease (ESRD) and can result in excessive parathyroid hormone (PTH) secretion, leading to osteodystrophy, bone fractures, and increased risks of mortality and cardiovascular events (1–4).